Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real‐life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists. Issue 11 (22nd September 2022)

• Record Type: Journal Article
• Authors: Mahé, Emmanuel; Beauchet, Alain; Hadj‐Rabia, Smaïl; Mazereeuw‐Hautier, Juliette; Mallet, Stéphanie; Phan, Alice; Severino‐Freire, Maëlle; Boralevi, Franck; Aubert, Hélène; Barthélémy, Hugue; Girard, Céline; Martin, Ludovic; Piram, Maryam; Barbarot, Sébastien; Balguerie, Xavier; Zitouni, Jinane; Phan, Céline; Di Lernia, Vito
• Is Part Of: Dermatologic therapy. Volume 35:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-22
• Subjects: acitretin -- adolescents -- biologic therapies -- children -- combine therapies -- cyclosporine -- methotrexate -- psoriasis; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15828
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Combined therapies involve the use of multiple drugs to increase efficacy and reduce the toxicity of individual treatments. We evaluated the use of combinations of conventional systemic therapies and biologics in children with psoriasis in daily practice. This two‐part study used data from the 170 children in the Franco‐Italian BiPe cohorts to evaluate the use, efficacy, and safety of combined conventional systemic–biologic therapies, and from a survey carried out among French and Italian dermatologists to better understand the reasons for using or avoiding these combinations. In total, 33 children (19.4%) from 13 dermatology centers received 48 combined conventional systemic–biologic therapies (cumulative duration: 43.6 years), including three triple combination therapies (acitretin–methotrexate, with a TNF‐alpha inhibitor). A total of 14 different combinations were used, most frequently etanercept–acitretin ( n = 10), adalimumab–acitretin ( n = 7), adalimumab–methotrexate ( n = 5), and ustekinumab–methotrexate ( n = 5). The combined therapies were started at biologic initiation in 41 cases (85.4%), and after a period of biologic monotherapy in the remaining 7 cases. Mean PGA and PASI scores decreased between baseline and M3 with all the combinations used. Four serious adverse events were reported, all with favorable outcomes. The survey was completed by 61 dermatologists: 39 (63.9%) had previously used or planned to use the combined therapies, most commonly TNF‐alpha inhibitors with acitretin or methotrexate. The main reason for using these treatments was to improve the outcome of biologic therapies in cases of partial efficacy or loss of efficacy. Combined therapies have been used frequently in the treatment of childhood psoriasis, in a range of clinical situations and in variable drug combinations, without significant toxicity. Although the use of these combined therapies needs to be clarified in future management guidelines, these combined therapies should be considered for the treatment of children with severe psoriasis, psoriatic arthritis, and recalcitrant disease.